EUROFINS SCIENTIFIC (ERF.PA) Fundamental Analysis & Valuation

EPA:ERF • FR0014000MR3

Current stock price

69.24 EUR
-0.2 (-0.29%)
Last:

This ERF.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ERF.PA Profitability Analysis

1.1 Basic Checks

  • ERF had positive earnings in the past year.
  • In the past year ERF had a positive cash flow from operations.
  • Each year in the past 5 years ERF has been profitable.
  • In the past 5 years ERF always reported a positive cash flow from operatings.
ERF.PA Yearly Net Income VS EBIT VS OCF VS FCFERF.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

1.2 Ratios

  • The Return On Assets of ERF (3.73%) is comparable to the rest of the industry.
  • With a decent Return On Equity value of 9.02%, ERF is doing good in the industry, outperforming 61.11% of the companies in the same industry.
  • The Return On Invested Capital of ERF (6.74%) is better than 66.67% of its industry peers.
  • ERF had an Average Return On Invested Capital over the past 3 years of 6.44%. This is below the industry average of 9.03%.
  • The last Return On Invested Capital (6.74%) for ERF is above the 3 year average (6.44%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.73%
ROE 9.02%
ROIC 6.74%
ROA(3y)3.11%
ROA(5y)4.62%
ROE(3y)6.89%
ROE(5y)9.79%
ROIC(3y)6.44%
ROIC(5y)8.49%
ERF.PA Yearly ROA, ROE, ROICERF.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With a Profit Margin value of 5.62%, ERF perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ERF has declined.
  • ERF has a Operating Margin of 10.87%. This is in the lower half of the industry: ERF underperforms 66.67% of its industry peers.
  • ERF's Operating Margin has declined in the last couple of years.
  • With a Gross Margin value of 21.39%, ERF is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • ERF's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.87%
PM (TTM) 5.62%
GM 21.4%
OM growth 3Y-11.04%
OM growth 5Y-10.39%
PM growth 3Y-13.43%
PM growth 5Y-9.58%
GM growth 3Y-1.72%
GM growth 5Y-3.8%
ERF.PA Yearly Profit, Operating, Gross MarginsERF.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

5

2. ERF.PA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ERF is destroying value.
  • ERF has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ERF has less shares outstanding
  • Compared to 1 year ago, ERF has a worse debt to assets ratio.
ERF.PA Yearly Shares OutstandingERF.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ERF.PA Yearly Total Debt VS Total AssetsERF.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • ERF has an Altman-Z score of 2.59. This is not the best score and indicates that ERF is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ERF has a Altman-Z score (2.59) which is in line with its industry peers.
  • The Debt to FCF ratio of ERF is 5.14, which is a neutral value as it means it would take ERF, 5.14 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of ERF (5.14) is better than 77.78% of its industry peers.
  • A Debt/Equity ratio of 0.82 indicates that ERF is somewhat dependend on debt financing.
  • ERF has a Debt to Equity ratio (0.82) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF 5.14
Altman-Z 2.59
ROIC/WACC0.89
WACC7.61%
ERF.PA Yearly LT Debt VS Equity VS FCFERF.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • ERF has a Current Ratio of 1.09. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of ERF (1.09) is comparable to the rest of the industry.
  • A Quick Ratio of 1.03 indicates that ERF should not have too much problems paying its short term obligations.
  • ERF has a Quick ratio (1.03) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.03
ERF.PA Yearly Current Assets VS Current LiabilitesERF.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

5

3. ERF.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.73% over the past year.
  • ERF shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.09% yearly.
  • ERF shows a small growth in Revenue. In the last year, the Revenue has grown by 4.96%.
  • ERF shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)12.73%
EPS 3Y-8.95%
EPS 5Y-3.09%
EPS Q2Q%6.78%
Revenue 1Y (TTM)4.96%
Revenue growth 3Y2.82%
Revenue growth 5Y6.05%
Sales Q2Q%4.3%

3.2 Future

  • ERF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.11% yearly.
  • The Revenue is expected to grow by 7.47% on average over the next years.
EPS Next Y6.38%
EPS Next 2Y11.18%
EPS Next 3Y13.59%
EPS Next 5Y16.11%
Revenue Next Year4.44%
Revenue Next 2Y5.49%
Revenue Next 3Y5.78%
Revenue Next 5Y7.47%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ERF.PA Yearly Revenue VS EstimatesERF.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B
ERF.PA Yearly EPS VS EstimatesERF.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

5

4. ERF.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 18.61, ERF is valued on the expensive side.
  • Based on the Price/Earnings ratio, ERF is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.38. ERF is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 18.07, ERF is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, ERF is valued a bit cheaper than 72.22% of the companies in the same industry.
  • ERF is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.61
Fwd PE 18.07
ERF.PA Price Earnings VS Forward Price EarningsERF.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 83.33% of the companies in the same industry are more expensive than ERF, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ERF indicates a rather cheap valuation: ERF is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.13
EV/EBITDA 10.46
ERF.PA Per share dataERF.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as ERF's earnings are expected to grow with 13.59% in the coming years.
PEG (NY)2.92
PEG (5Y)N/A
EPS Next 2Y11.18%
EPS Next 3Y13.59%

6

5. ERF.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.13%, ERF has a reasonable but not impressive dividend return.
  • ERF's Dividend Yield is rather good when compared to the industry average which is at 0.52. ERF pays more dividend than 83.33% of the companies in the same industry.
  • ERF's Dividend Yield is slightly below the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.13%

5.2 History

  • The dividend of ERF is nicely growing with an annual growth rate of 16.09%!
Dividend Growth(5Y)16.09%
Div Incr Years1
Div Non Decr Years1
ERF.PA Yearly Dividends per shareERF.PA Yearly Dividends per shareYearly Dividends per share 2018 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 26.80% of the earnings are spent on dividend by ERF. This is a low number and sustainable payout ratio.
  • ERF's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP26.8%
EPS Next 2Y11.18%
EPS Next 3Y13.59%
ERF.PA Yearly Income VS Free CF VS DividendERF.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
ERF.PA Dividend Payout.ERF.PA Dividend Payout, showing the Payout Ratio.ERF.PA Dividend Payout.PayoutRetained Earnings

ERF.PA Fundamentals: All Metrics, Ratios and Statistics

EUROFINS SCIENTIFIC

EPA:ERF (4/16/2026, 5:36:15 PM)

69.24

-0.2 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-29
Earnings (Next)04-22
Inst Owners35.09%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap12.19B
Revenue(TTM)7.30B
Net Income(TTM)409.70M
Analysts72
Price Target72.19 (4.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.13%
Yearly Dividend0.6
Dividend Growth(5Y)16.09%
DP26.8%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.3%
PT rev (3m)9.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.79%
EPS NY rev (3m)-3.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)-1.21%
Valuation
Industry RankSector Rank
PE 18.61
Fwd PE 18.07
P/S 1.67
P/FCF 14.13
P/OCF 8.71
P/B 2.68
P/tB N/A
EV/EBITDA 10.46
EPS(TTM)3.72
EY5.37%
EPS(NY)3.83
Fwd EY5.53%
FCF(TTM)4.9
FCFY7.08%
OCF(TTM)7.95
OCFY11.48%
SpS41.46
BVpS25.81
TBVpS-4.57
PEG (NY)2.92
PEG (5Y)N/A
Graham Number46.4828 (-32.87%)
Profitability
Industry RankSector Rank
ROA 3.73%
ROE 9.02%
ROCE 9.27%
ROIC 6.74%
ROICexc 7.43%
ROICexgc 23.86%
OM 10.87%
PM (TTM) 5.62%
GM 21.4%
FCFM 11.82%
ROA(3y)3.11%
ROA(5y)4.62%
ROE(3y)6.89%
ROE(5y)9.79%
ROIC(3y)6.44%
ROIC(5y)8.49%
ROICexc(3y)7.17%
ROICexc(5y)9.25%
ROICexgc(3y)23.01%
ROICexgc(5y)30.49%
ROCE(3y)8.97%
ROCE(5y)11.81%
ROICexgc growth 3Y-10.94%
ROICexgc growth 5Y-13.82%
ROICexc growth 3Y-8.95%
ROICexc growth 5Y-10.36%
OM growth 3Y-11.04%
OM growth 5Y-10.39%
PM growth 3Y-13.43%
PM growth 5Y-9.58%
GM growth 3Y-1.72%
GM growth 5Y-3.8%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF 5.14
Debt/EBITDA 2.44
Cap/Depr 74.23%
Cap/Sales 7.35%
Interest Coverage 6.87
Cash Conversion 92.26%
Profit Quality 210.5%
Current Ratio 1.09
Quick Ratio 1.03
Altman-Z 2.59
F-Score7
WACC7.61%
ROIC/WACC0.89
Cap/Depr(3y)77.81%
Cap/Depr(5y)87.04%
Cap/Sales(3y)7.8%
Cap/Sales(5y)8.15%
Profit Quality(3y)205.64%
Profit Quality(5y)166.63%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y-8.95%
EPS 5Y-3.09%
EPS Q2Q%6.78%
EPS Next Y6.38%
EPS Next 2Y11.18%
EPS Next 3Y13.59%
EPS Next 5Y16.11%
Revenue 1Y (TTM)4.96%
Revenue growth 3Y2.82%
Revenue growth 5Y6.05%
Sales Q2Q%4.3%
Revenue Next Year4.44%
Revenue Next 2Y5.49%
Revenue Next 3Y5.78%
Revenue Next 5Y7.47%
EBIT growth 1Y-4.65%
EBIT growth 3Y-8.54%
EBIT growth 5Y-4.97%
EBIT Next Year81.58%
EBIT Next 3Y28.7%
EBIT Next 5Y24.78%
FCF growth 1Y9.1%
FCF growth 3Y21.91%
FCF growth 5Y-0.13%
OCF growth 1Y6.07%
OCF growth 3Y7.18%
OCF growth 5Y2.72%

EUROFINS SCIENTIFIC / ERF.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of EUROFINS SCIENTIFIC (ERF.PA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ERF.PA.


What is the valuation status for ERF stock?

ChartMill assigns a valuation rating of 5 / 10 to EUROFINS SCIENTIFIC (ERF.PA). This can be considered as Fairly Valued.


What is the profitability of ERF stock?

EUROFINS SCIENTIFIC (ERF.PA) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for ERF stock?

The Price/Earnings (PE) ratio for EUROFINS SCIENTIFIC (ERF.PA) is 18.61 and the Price/Book (PB) ratio is 2.68.


What is the financial health of EUROFINS SCIENTIFIC (ERF.PA) stock?

The financial health rating of EUROFINS SCIENTIFIC (ERF.PA) is 4 / 10.